

Linezolid 2 mg/ml

Solution for infusion

Linezolid

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1. What Linezolid Infusion is and what it is used for
2. What you need to know before you are treated with Linezolid Infusion
3. How to use Linezolid Infusion
4. Possible side effects
5. How to store Linezolid Infusion
6. Contents of the pack and other information

1. WHAT LINEZOLID INFUSION IS AND WHAT IT IS USED FOR

Linezolid Infusion is an antibiotic of the oxazolidinones group that works by stopping the growth of certain bacteria (germs) that cause infections. It is used to treat pneumonia and some infections in the skin or under the skin. Your doctor will have decided if Linezolid Infusion is suitable to treat your infection.

2. WHAT YOU NEED TO KNOW BEFORE YOU ARE TREATED WITH LINEZOLID INFUSION

Do not use Linezolid Infusion:

- if you are allergic to linezolid or any of the other ingredients of this medicine (listed in section 6)
- if you are taking or have taken within the last 2 weeks any medicines known as monoamine oxidase inhibitors (MAOIs for example phenelzine, isocarboxazid, selegiline, moclobemide). These may be used to treat depression or Parkinson's disease
- if you are breast-feeding. This is because Linezolid Infusion passes into breast milk and could affect the baby.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before using Linezolid Infusion.

Linezolid Infusion may not be suitable for you if you answer yes to any of the following questions. In these cases tell your doctor as he/she will need to check your general health and your blood pressure before and during your treatment or may decide that another treatment is better for you.

Ask your doctor if you are not sure whether these categories apply to you.

- Do you have high blood pressure, whether or not you are taking medicines for this?
- Have you been diagnosed with an overactive thyroid?
- Do you have a tumour of the adrenal glands (phaeochromocytoma) or carcinoid syndrome (caused by tumours of the hormone system with symptoms of diarrhoea, flushing of the skin, wheezing)?
- Do you suffer from manic depression, schizoaffective disorder, mental confusion or other mental problems?

Take special care with Linezolid Infusion.

Tell your doctor before you take this medicine if you:

- bruise and bleed easily
- are anaemic (have low red blood cells)
- are prone to getting infections
- have a history of seizures
- have liver problems or kidney problems particularly if you are on dialysis
- have diarrhoea

Tell your doctor immediately if during treatment you suffer from:

- problems with your vision such as blurred vision, changes in colour vision, difficulty in seeing detail or if your field of vision becomes restricted.
- loss of sensitivity in your arms or legs or a sensation of tingling or pricking in your arm or legs.
- you may develop diarrhoea while taking or after taking antibiotics, including Linezolid Infusion. If this becomes severe or persistent or you notice that your stool contains blood or mucus, you should stop taking Linezolid Infusion immediately and consult your doctor. In this situation, you should not take medicines that stop or slow bowel movement.
- recurrent nausea or vomiting, abdominal pain or rapid breathing.

Other medicines and Linezolid Infusion

There is a risk that Linezolid Infusion may sometimes interact with certain other medicines to cause side effects such as changes in blood pressure, temperature or heart rate.

Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.



Linezolid 2 mg/ml solution for infusion

Linezolid

IMPORTANT: Refer to Summary of Product Characteristics (SPC) before prescribing.

Linezolid is not active against infections caused by Gram negative pathogens. Specific therapy against Gram negative organisms must be initiated concomitantly if co-infection with a Gram negative pathogen is documented or suspected.

Description

Single use, ready-to-use, latex-free, made of multilayered polyolefine film infusion bags (Excel or Freeflex) sealed inside a foil laminate overwrap. The bag holds 300 ml solution and is packaged in a box. Each box contains 1, 10 or 25 infusion bags.

Linezolid Infusion contains linezolid 2 mg/ml in an isotonic, clear, colourless to yellow solution. Other ingredients are: glucose monohydrate, sodium citrate, citric acid anhydrous, hydrochloric acid or sodium hydroxide, water for injections.

Dosage and Method of Administration

Linezolid should only be initiated in a hospital environment and after consultation with a relevant specialist such as a microbiologist or an infectious diseases specialist.

Patients who commence treatment on the parenteral formulation may be switched to either oral presentation when clinically indicated. In such circumstances, no dose adjustment is required as linezolid has an oral bioavailability of approximately 100 %.

The solution for infusion should be administered over a period of 30 to 120 minutes.

The recommended linezolid dosage should be administered intravenously (IV) twice daily.

Recommended dosage and duration for adults:

The duration of treatment is dependent on the pathogen, the site of infection and its severity, and on the patient's clinical response.

The following recommendations for duration of therapy reflect those used in the clinical trials. Shorter treatment regimens may be suitable for some types of infection but have not been evaluated in clinical trials.

The maximum treatment duration is 28 days. The safety and effectiveness of linezolid have not yet been established for treatment periods longer than 28 days.

No increase in the recommended dosage or duration of treatment is required for infections associated with concurrent bacteraemia.

The dose recommendation for Linezolid 2 mg/ml Solution for Infusion is the following:

Infections	Dosage	Duration of treatment
Nosocomial pneumonia	600 mg twice daily	10-14 Consecutive days
Community acquired pneumonia		
Complicated skin and soft tissue infections	600 mg twice daily	

Paediatric population:

The safety and efficacy of linezolid in children aged (< 18 years old) has not been established. Currently available data are described in section 4.8, 5.1, and 5.2 of the SmPC but no recommendation on a posology can be made.

Elderly:

No dose adjustment is required.

Renal impairment:

No dose adjustment is required.

Severe renal impairment (i.e. CLCR < 30 ml/min):

No dose adjustment is required. Due to the unknown clinical significance of higher exposure (up to 10-fold) to the two primary metabolites of linezolid in patients with severe renal insufficiency, linezolid should be used with special caution in these patients and only when the anticipated benefit is considered to outweigh the theoretical risk.

As approximately 30 % of a linezolid dose is removed during 3 hours of haemodialysis, Linezolid 2 mg/ml Solution for Infusion should be given after dialysis in patients receiving such treatment. The primary metabolites of linezolid are removed to some extent by haemodialysis, but the concentrations of these metabolites are still very considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency. Therefore, linezolid should be used with special caution in patients with severe renal insufficiency who are undergoing dialysis, and only when the anticipated benefit is considered to outweigh the theoretical risk.

To date, there is no experience of linezolid administration to patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or alternative treatments for renal failure (other than haemodialysis).

Hepatic impairment:

Patients with mild to moderate hepatic insufficiency (Child-Pugh class A or B): No dose adjustment is required.

Severe hepatic impairment (Child-Pugh class C): As linezolid is metabolised by a non-enzymatic process, impairment of hepatic function would not be expected to significantly alter its metabolism and, therefore, no dose adjustment is recommended. However, there are limited clinical data and it is recommended that linezolid should be used in such patients only when the anticipated benefit is considered to outweigh the theoretical risk (see sections 4.4 and 5.2 of the SmPC).

Contraindications

Patients hypersensitive to linezolid or any of the excipients.

Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid, selegiline, moclobemide) or within two weeks of taking any such medicinal product.

Unless there are facilities available for close observation and monitoring of blood pressure, linezolid should not be administered to patients with the following underlying clinical conditions or on the following types of concomitant medications:

- Patients with uncontrolled hypertension, phaeochromocytoma, carcinoid, thyrotoxicosis, bipolar depression, schizoaffective disorder, acute confusional states.
- Patients taking any of the following medications: Serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans), directly and indirectly acting sympathomimetic agents (including the adrenergic bronchodilators, pseudoephedrine and phenylpropanolamine), vasopressor agents (e.g., adrenaline / epinephrine, noradrenaline / norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine), pethidine or buspirone.

Breast feeding should be discontinued prior to and throughout administration (see section 4.6 of SmPC).

Special warnings and precautions for use

Myelosuppression

Myelosuppression (including anaemia, leucopenia, pancytopenia and thrombocytopenia) has been reported in patients receiving linezolid. In cases where the outcome is known, when linezolid was discontinued, the affected haematologic parameters have risen toward pretreatment levels. The risk of these effects appears to be related to the duration of treatment. Elderly patients treated with linezolid may be at greater risk of experiencing blood dyscrasias than younger patients. Thrombocytopenia may occur more commonly in patients with severe renal insufficiency, whether or not on dialysis. Therefore, close monitoring of blood counts is recommended in patients who: have pre-existing anaemia, granulocytopenia or thrombocytopenia; are receiving concomitant medications that may decrease haemoglobin levels, depressed blood counts or adversely affect platelet count or function; have severe renal insufficiency; receive more than 10-14 days of therapy. Linezolid should be administered to such patients only when close monitoring of haemoglobin levels, blood counts and platelet counts is possible.

If significant myelosuppression occurs during linezolid therapy, treatment should be stopped unless it is considered absolutely necessary to continue therapy, in which case intensive monitoring of blood counts and appropriate management strategies should be implemented.

In addition, it is recommended that complete blood counts (including haemoglobin levels, platelets, and total and differentiated leucocyte counts) should be monitored weekly in patients who receive linezolid regardless of baseline blood count.

In compassionate use studies, a higher incidence of serious anaemia was reported in patients receiving linezolid for more than the maximum recommended duration of 28 days. These patients more often required blood transfusion. Cases of anaemia requiring blood transfusion have also been reported post marketing, with more cases occurring in patients who received linezolid therapy for more than 28 days.

Cases of sideroblastic anaemia have been reported post-marketing. Where time of onset was known, most patients had received linezolid therapy for more than 28 days. Most patients fully or partially recovered following discontinuation of linezolid with or without treatment for their anaemia.

Mortality imbalance in a clinical trial in patients with catheter-related Gram positive bloodstream infections.

Excess mortality was seen in patients treated with linezolid, relative to vancomycin/dicloxacillin/oxacil-

lin, in an open-label study in seriously ill patients with intravascular catheter-related infections [78/363 (21.5%) vs 58/363 (16.0%)]. The main factor influencing the mortality rate was the Gram positive infection status at baseline. Mortality rates were similar in patients with infections caused purely by Gram positive organisms (odds ratio 0.96; 95% confidence interval: 0.58-1.59) but were significantly higher (p=0.0162) in the linezolid arm in patients with any other pathogen or no pathogen at baseline (odds ratio 2.48; 95% confidence interval: 1.38-4.46). The greatest imbalance occurred during treatment and within 7 days following discontinuation of study drug. More patients in the linezolid arm acquired Gram negative pathogens during the study and died from infection caused by Gram negative pathogens and polymicrobial infections. Therefore, in complicated skin and soft tissue infections linezolid should only be used in patients with known or possible co-infection with Gram negative organisms if there are no alternative treatment options available. In these circumstances treatment against Gram negative organisms must be initiated concomitantly.

Antibiotic-associated diarrhoea and colitis

Antibiotic-associated diarrhoea and antibiotic-associated colitis, including pseudomembranous colitis and *Clostridium difficile*-associated diarrhoea, has been reported in association with the use of nearly all antibiotics including linezolid and may range in severity from mild diarrhoea to fatal colitis. Therefore, it is important to consider this diagnosis in patients who develop serious diarrhoea during or after the use of linezolid. If antibiotic-associated diarrhoea or antibiotic-associated colitis is suspected or confirmed, ongoing treatment with antibacterial agents, including linezolid, should be discontinued and adequate therapeutic measures should be initiated immediately. Drugs inhibiting peristalsis are contraindicated in this situation.

Lactic acidosis

Lactic acidosis has been reported with the use of linezolid. Patients who develop signs and symptoms of metabolic acidosis including recurrent nausea or vomiting, abdominal pain, a low bicarbonate level, or hyperventilation while receiving linezolid should receive immediate medical attention. If lactic acidosis occurs, the benefits of continued use of linezolid should be weighed against the potential risks.

Mitochondrial dysfunction

Linezolid inhibits mitochondrial protein synthesis. Adverse events, such as lactic acidosis, anaemia and neuropathy (optic and peripheral), may occur as a result of this inhibition; these events are more common when the drug is used longer than 28 days.

Serotonin syndrome

Spontaneous reports of serotonin syndrome, a potentially life-threatening condition, associated with the co-administration of linezolid and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs) have been reported. Co-administration of linezolid and serotonergic agents is therefore contraindicated except where administration of linezolid and concomitant serotonergic agents is essential. In those cases patients should be closely observed for signs and symptoms of serotonin syndrome such as cognitive dysfunction, hyperpyrexia, hyperreflexia and incoordination. If signs or symptoms occur physicians should consider discontinuing either one or both agents; if the concomitant serotonergic agent is withdrawn, discontinuation symptoms can occur. Occurrence of serotonin syndrome has been also reported with concomitant administration of linezolid and buprenorphine.

Peripheral and optic neuropathy

Peripheral neuropathy, as well as optic neuropathy and optic neuritis sometimes progressing to loss of vision, have been reported in patients treated with Linezolid Infusion; these reports have primarily been in patients treated for longer than the maximum recommended duration of 28 days.

All patients should be advised to report symptoms of visual impairment, such as changes in visual acuity, changes in colour vision, blurred vision, or visual field defect. In such cases, prompt evaluation is recommended with referral to an ophthalmologist as necessary. If any patients are taking Linezolid Infusion for longer than the recommended 28 days, their visual function should be regularly monitored.

If peripheral or optic neuropathy occurs, the continued use of Linezolid Infusion should be weighed against the potential risks.

There may be an increased risk of neuropathies when linezolid is used in patients currently taking or who have recently taken antimycobacterial medications for the treatment of tuberculosis.

Convulsions

Convulsions have been reported to occur in patients when treated with Linezolid Infusion. In most of these cases, a history of seizures or risk factors for seizures was reported. Patients should be advised to inform their physician if they have a history of seizures.

Monoamine oxidase inhibitors

Linezolid is a reversible, non-selective inhibitor of monoamine oxidase (MAOI); however, at the doses used for antibacterial therapy, it does not exert an anti-depressive effect. There are very limited data from drug interaction studies and on the safety of linezolid when administered to patients with underlying conditions and/or on concomitant medications which might put them at risk from MAO inhibition. Therefore, linezolid is not recommended for use in these circumstances unless close observation and monitoring of the recipient is possible.

Use with tyramine-rich foods

Patients should be advised against consuming large amounts of tyramine-rich foods.

Superinfection

The effects of linezolid therapy on normal flora have not been evaluated in clinical trials. The use of antibiotics may occasionally result in an overgrowth of non-susceptible organisms. For example, approximately 3% of patients receiving the recommended linezolid doses experienced drug-related candidiasis during clinical trials. Should superinfection occur during therapy, appropriate measures should be taken.

Special populations

Linezolid should be used with special caution in patients with severe renal insufficiency and only when the anticipated benefit is considered to outweigh the theoretical risk (see sections 4.2 and 5.2 of the SmPC). It is recommended that linezolid should be given to patients with severe hepatic insufficiency only when the perceived benefit outweighs the theoretical risk.

Impairment of fertility

Linezolid reversibly decreased fertility and induced abnormal sperm morphology in adult male rats at exposure levels approximately equal to those expected in humans; possible effects of linezolid on the human male reproductive system are not known.

Clinical trials

The safety and effectiveness of linezolid when administered for periods longer than 28 days have not been established.

Controlled clinical trials did not include patients with diabetic foot lesions, decubitus or ischaemic lesions, severe burns or gangrene. Therefore, experience in the use of linezolid in the treatment of these conditions is limited.

Excipients

Each ml of the solution contains 45.7 mg (i.e. 13.7 g/300 ml) glucose. This should be taken into account in patients with diabetes mellitus or other conditions associated with glucose intolerance. This medicine contains 0.38 mg sodium (main component of cooking/table salt) for each ml (114 mg sodium per infusion bag of 300 ml). This is equivalent to 5.7% of the recommended maximum daily dietary intake of sodium for an adult.

Interactions

Monoamine oxidase inhibitors

Linezolid is a reversible, non-selective inhibitor of monoamine oxidase (MAOI). There are very limited data from drug interaction studies and on the safety of linezolid when administered to patients on concomitant medications that might put them at risk from MAO inhibition. Therefore, linezolid is not recommended for use in these circumstances unless close observation and monitoring of the recipient is possible.

Potential interactions producing elevation of blood pressure

In normotensive healthy volunteers, linezolid enhanced the increases in blood pressure caused by pseudoephedrine and phenylpropanolamine hydrochloride. Co-administration of linezolid with either pseudoephedrine or phenylpropanolamine resulted in mean increases in systolic blood pressure of the order of 30-40 mm Hg, compared with 11-15 mm Hg increases with linezolid alone, 14-18 mm Hg with either pseudoephedrine or phenylpropanolamine alone and 8-11 mm Hg with placebo. Similar studies in hypertensive subjects have not been conducted. It is recommended that doses of drugs with a vasopressor action, including dopaminergic agents, should be carefully titrated to achieve the desired response when co-administered with linezolid.

Potential serotonergic interactions

The potential drug-drug interaction with dextromethorphan was studied in healthy volunteers. Subjects were administered dextromethorphan (two 20 mg doses given 4 hours apart) with or without linezolid. No serotonin syndrome effects (confusion, delirium, restlessness, tremors, blushing, diaphoresis and hyperpyrexia) have been observed in normal subjects receiving linezolid and dextromethorphan.

Post marketing experience: there has been one report of a patient experiencing serotonin syndrome-like effects while taking linezolid and dextromethorphan which resolved on discontinuation of both medications. Linezolid should be used cautiously when co-administered with buprenorphine as the risk of serotonin

A course of treatment usually lasts 10 to 14 days, but can last up to 28 days. The safety and effectiveness of this medicine have not been established for treatment periods longer than 28 days. Your doctor will decide how long you should be treated.

While you are taking Linezolid Infusion, your doctor should perform regular blood tests to monitor your blood count.

Your doctor should monitor your eyesight if you take Linezolid Infusion for more than 28 days.

Use in children and adolescents

Linezolid Infusion is not normally used to treat children and adolescents (under 18 years old).

If you use more Linezolid Infusion than you should

If you are concerned that you may have been given too much Linezolid Infusion, tell your doctor or nurse at once.

If you forget to use Linezolid Infusion

As you will be given this medicine under close supervision, it is very unlikely that you will miss a dose. If you think that you have missed a dose of treatment, tell a doctor or nurse at once. Do not take a double dose to make up for a forgotten dose.

4. POSSIBLE SIDE EFFECTS

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor or pharmacist or nurse immediately if you notice any of these side effects during your treatment with Linezolid Infusion:

The serious side effects (with frequency in brackets) of Linezolid Infusion are:

- Severe skin disorders (not known) swelling, particularly around the face and neck (not known) wheezing and/or difficulty breathing (not known). This may be the sign of an allergic reaction and it may be necessary for you to stop taking Linezolid Infusion. Skin reactions such as red sore skin and flaking (dermatitis) (uncommon), rash (common), itching (common).
- Problems with your vision such as blurred vision (uncommon), changes in colour vision (not known), difficulty in seeing detail (not known) or if your field of vision becomes restricted (rare).
- Severe diarrhoea containing blood and/or mucus (antibiotic associated colitis including pseudomembranous colitis), which in rare circumstances may develop into complications that are life-threatening.
- Recurrent nausea or vomiting, abdominal pain or rapid breathing (not known).
- Fits or seizures (uncommon) have been reported with Linezolid Infusion . You should let your doctor know if you experience agitation, confusion, delirium, rigidity, tremor, incoordination and seizure while also taking antidepressants known as SSRI's (see section 2) (not known).
- Unexplained bleeding or bruising, which may be due to changes in the numbers of certain cells in the blood which may affect blood clotting or lead to anaemia (common).
- Changes in numbers of certain cells in the blood which may affect your ability to fight infection (common) some signs of infection include: any fever (common), sore throat (uncommon), mouth ulcers (uncommon) and tiredness (uncommon).
- Inflammation of the pancreas (uncommon).
- Convulsions (uncommon).
- Transient ischaemic attacks (temporary disturbance of blood flow to the brain causing short term symptoms such as loss of vision, leg and arm weakness, slurring of speech and loss of consciousness) (uncommon).
- "Ringing" in the ears (tinnitus) (uncommon).

Numbness, tingling or blurred vision have been reported by patients who have been given Linezolid Infusion for more than 28 days. If you experience difficulties with your vision you should consult your doctor as soon as possible.

Other side effects include:

Common (may affect up to 1 in 10 people):

- Fungal infections especially vaginal or oral "thrush"
- Headache
- Metallic taste in the mouth
- Diarrhoea, nausea or vomiting
- Changes in some blood test results including those measuring your kidney or liver function or blood sugar levels
- Difficulty in sleeping
- Increased blood pressure
- Anaemia (low red blood cell)
- Dizziness
- Localised or general abdominal pain
- Constipation
- Indigestion
- Localised pain

Uncommon (may affect up to 1 in 100 people):

- Inflammation of the vagina or genital area in women
- Sensation such as tingling or feeling numb
- Swollen, sore, or discoloured tongue
- Pain at and around the place where the infusion (drip) was given
- Inflammation of the veins (including where the infusion (drip) was given)



syndrome, a potentially life-threatening condition, is increased (see section 4.4 of the SmPc). During clinical use of linezolid with serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), cases of serotonin syndrome have been reported. Therefore, while co-administration is contraindicated, management of patients for whom treatment with linezolid and serotonergic agents is essential, is described in special warnings and precautions for use.

Use with tyramine-rich foods

No significant pressor response was observed in subjects receiving both linezolid and less than 100 mg tyramine. This suggests that it is only necessary to avoid ingesting excessive amounts of food and beverages with a high tyramine content (e.g., mature cheese, yeast extracts, undistilled alcoholic beverages and fermented soya bean products such as soy sauce).

Drugs metabolised by cytochrome P450

Linezolid is not detectably metabolised by the cytochrome P450 (CYP) enzyme system and it does not inhibit any of the clinically significant human CYP isoforms (1A2, 2C9, 2C19, 2D6, 2E1, 3A4). Similarly, linezolid does not induce P450 isoenzymes in rats. Therefore, no CYP450-induced drug interactions are expected with linezolid.

Rifampicin

The effect of rifampicin on the pharmacokinetics of linezolid was studied in sixteen healthy adult male volunteers administered linezolid 600 mg twice daily for 2.5 days with and without rifampicin 600 mg once daily for 8 days. Rifampicin decreased the linezolid Cmax and AUC by a mean 21% [90% CI, 15, 27] and a mean 32% [90% CI, 27, 37], respectively. The mechanism of this interaction and its clinical significance are unknown.

Warfarin

When warfarin was added to linezolid therapy at steady-state, there was a 10% reduction in mean maximum INR on co-administration with a 5% reduction in AUC INR. There are insufficient data from patients who have received warfarin and linezolid to assess the clinical significance, if any, of these findings.

Fertility, pregnancy and lactation

Pregnancy

There are limited data from the use of linezolid in pregnant women. Studies in animals have shown reproductive toxicity. A potential risk for humans exists.

Linezolid should not be used during pregnancy unless clearly necessary i.e. only if the potential benefit outweighs the theoretical risk.

Breast-feeding

Animal data suggest that linezolid and its metabolites may pass into breast milk and, accordingly, breast-feeding should be discontinued prior to and throughout administration.

Fertility

In animal studies, linezolid caused a reduction in fertility

Effects on ability to drive and use machines

Patients should be warned about the potential for dizziness or symptoms of visual impairment whilst receiving linezolid and should be advised not to drive or operate machinery if any of these symptoms occurs.

Undesirable effects

The table below provides a listing of adverse drug reactions with frequency based on all-causality data from clinical studies that enrolled more than 2,000 adult patients who received the recommended linezolid doses for up to 28 days. Those most commonly reported were diarrhoea (8.4%), headache (6.5%), nausea (6.3%) and vomiting (4.0%).

The most commonly reported drug-related adverse events which led to discontinuation of treatment were headache, diarrhoea, nausea and vomiting. About 3 % of patients discontinued treatment because they experienced a drug-related adverse event.

Additional adverse reactions reported from post-marketing experience are included in the table with frequency category 'Not known', since the actual frequency cannot be estimated from the available data.

The following undesirable effects have been observed and reported during treatment with linezolid with the following frequencies:

very common (≥1/10);	rare (≥1/10,000 to <1/1,000);
common (≥1/100 to <1/10);	very rare (<1/10,000);
uncommon (≥1/1,000 to <1/100);	Not known (cannot be estimated from the available data)

System Organ Class	Common (≥1/100 to <1/10)	Uncommon (≥1/1,000 to <1/100)	Rare (≥1/10,000 to <1/1,000)	Very Rare (<1/10,000)	Frequency not known (cannot be estimated from available data)
Infections and infestations	candidiasis, oral candidiasis, vaginal candidiasis, fungal infections	vaginitis	antibiotic associated colitis, including pseudomembranous colitis*		
Blood and the lymphatic system disorders	anaemia*†	leucopenia*, neutropenia thrombocytopenia*, eosinophilia	pancytopenia*		myelosuppression*, sideroblastic anaemia*
Immune system disorders					anaphylaxis
Metabolism and nutrition disorders		hyponatraemia			lactic acidosis*
Psychiatric disorders	insomnia				
Nervous system disorders	headache, taste perversion (metallic taste), dizziness	convulsions*, hypoaesthesia, paraesthesia			serotonin syndrome**, peripheral neuropathy*
Eye disorders		blurred vision*	changes in visual field defect*		optic neuropathy*, optic neuritis*, loss of vision*, changes in visual acuity*, changes in colour vision*
Ear and labyrinth disorders		tinnitus			
Cardiac disorders		arrhythmia (tachycardia)			
Vascular disorders	hypertension	transient ischaemic attacks, phlebitis, thrombophlebitis			
Gastro-intestinal disorders	diarrhoea, nausea, vomiting, localised or general abdominal pain, constipation, dyspepsia	pancreatitis, gastritis, abdominal distention, dry mouth, glossitis loose stools, stomatitis, tongue discoloration or disorder	superficial tooth discoloration		
Hepatobiliary disorders	abnormal liver function test: increased AST, ALT or alkaline phosphatase	increased total bilirubin			

- A need to urinate more often
- Chills
- Feeling thirsty
- Increased sweating
- Changes in proteins, salts or enzymes in the blood which measure kidney or liver function
- Hyponatraemia (low blood sodium levels)
- Kidney failure
- Reduction in platelets
- Abdominal bloating
- Injection site pain
- Increase in creatinine
- Stomach pain
- Changes in heart rate (e.g. increase rate)

Rare (may affect up to 1 in 1000 people):

- Superficial tooth discoloration, removable with professional dental cleaning (manual descaling)

The following side effects have also been reported (Not known: frequency cannot be estimated from the available data):

- Alopecia (hair loss)
- Decrease of the blood cell count
- Weakness and/or sensory changes

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effect not listed in this leaflet. You can also report side effects directly via he Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.

5. HOW TO STORE LINEZOLID INFUSION

Keep this medicine out of the sight and reach of children.

Do not used this medicine after the expiry date which is stated on the carton, bags and overwrap after "EXP". The expiry date refers to the last day of that month.

Hospital Staff will make sure that Linezolid Infusion is not used after the 'EXP' date printed on the bag and that it is given to you as soon as the seal is broken. They will also visually inspect the solution prior to use and only clear solution, without particles will be used. They will also make sure that the solution is kept correctly in its box and foil wrapping in order to protect from light and out of the sight and reach of children until it is needed.

After opening:

From a microbiological point of view, unless the method of opening precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

Do not throw away via wastewater or household waste. Your pharmacist or nurse should dispose of medicines that are no longer required. These measures will help to protect the environment.

6. CONTENTS OF THE PACK AND OTHER INFORMATION

What Linezolid Infusion contains

- The active substance is linezolid. Each ml of solution contains 2 milligrams of linezolid. Each 300 ml infusion bag contains 600 mg linezolid.
- The other ingredients are glucose monohydrate (a type of sugar, see section 2), sodium citrate (see section 2), citric acid anhydrous, hydrochloric acid and sodium hydroxide and water for injections.

What Linezolid Infusion looks like and contents of the pack

Linezolid Infusion is presented as a clear solution in single infusion bags containing 300 ml of solution. The bags are supplied in boxes of 1, 10 or 25 bags.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

PANMEDICA

406 Bureaux de la Colline

92213 Saint-Cloud CEDEX,

France

Tel: +33 1 4761 8640

Fax: +33 1 4761 8641

E-mail: contact@panmedica.fr

Manufacturer

Infomed Fluids S.R.L

50 Theodor Pallady Blvd, District 3,

032266 Bucharest, Romania

Tel: +40 21 345 02 22

Fax: +40 21 345 3185

E-mail: office@infomedfluids.ro

This leaflet was last revised in 09/2021

The following information is intended for healthcare professionals only:

System Organ Class	Common (≥1/100 to <1/10)	Uncommon (≥1/1,000 to <1/100)	Rare (≥1/10,000 to <1/1,000)	Very Rare (<1/10,000)	Frequency not known (cannot be estimated from available data)
Skin and subcutaneous tissue disorders	pruritus, rash	urticaria, dermatitis, diaphoresis			bullous disorders such as those described as Stevens-Johnson syndrome and toxic epidermal necrolysis, angioedema, alopecia
Renal and urinary disorders	increased BUN	renal failure, increased creatinine, polyuria			
Reproductive system and breast disorders		vulvovaginal disorder			
General disorders and administration site conditions	fever, localised pain	chills, fatigue, injection site pain, increased thirst			
Investigations	<u>Chemistry</u> Increased LDH, creatine kinase, lipase, amylase or non fasting glucose. Decreased total protein albumin, sodium or calcium. Increased or decreased potassium or bicarbonate. <u>Haematology</u> Increased neutrophils or eosinophils. Decreased haemoglobin, haematocrit or red blood cell count. Increased or decreased platelet or white blood cell counts.	<u>Chemistry</u> Increased sodium or calcium. Decreased non fasting glucose. Increased or decreased chloride. <u>Haematology</u> Increased reticulocyte count. Decreased neutrophils.			

* See section Special warnings and precautions for use

** See sections Contraindications and Interactions

† See below

The following adverse reactions to linezolid were considered to be serious in rare cases: localised abdominal pain, transient ischaemic attacks and hypertension.

† In controlled clinical trials where linezolid was administered for up to 28 days, 2.0% of the patients reported anaemia. In a compassionate use program of patients with life-threatening infections and underlying co-morbidities, the percentage of patients who developed anaemia when receiving linezolid for ≤ 28 days was 2.5% (33/1326) as compared with 12.3% (53/430) when treated for > 28 days. The proportion of cases reporting drug-related serious anaemia and requiring blood transfusion was 9% (3/33) in patients treated for ≤ 28 days and 15% (8/53) in those treated for > 28 days.

Paediatric population

Safety data from clinical studies based on more than 500 paediatric patients (from birth to 17 years) do not indicate that the safety profile of linezolid for paediatric patients differs from that for adult patients.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V)

Overdose

No specific antidote is known.

No cases of overdose have been reported. However, the following information may prove useful: Supportive care is advised together with maintenance of glomerular filtration. Approximately 30% of a linezolid dose is removed during 3 hours of haemodialysis, but no data are available for the removal of linezolid by peritoneal dialysis or haemoperfusion.

Instructions for use and handling

For single use only. Remove overwrap only when ready to use, then check for minute leaks by squeezing the bag firmly. If the bag leaks, do not use as sterility may be impaired. The solution should be visually inspected prior to use and only clear solutions, without particles should be used. Do not use these bags in series connections. Any unused solution must be discarded. No special requirements for disposal Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Do not reconnect partially used bags.

Linezolid 2 mg/ml Solution for Infusion is compatible with the following solutions: Glucose 5% (50 mg/ml) Solution for Infusion, Sodium chloride 0.9% (9 mg/ml) Solution for Infusion, Ringer-lactate Solution for Injection (Hartmann's solution for injection).

Incompatibilities

Additives should not be introduced into this solution. If Linezolid 2 mg/ml Solution for Infusion is to be given concomitantly with other drugs, each drug should be given separately in accordance with its own directions for use. Similarly, if the same intravenous line is to be used for sequential infusion of several drugs, the line should be flushed prior to and following linezolid administration with a compatible infusion solution.

Linezolid 2 mg/ml Solution for Infusion is known to be physically incompatible with the following compounds: amphotericin B, chlorpromazine hydrochloride, diazepam, pentamidine isethionate, erythromycin lactobionate, phenytoin sodium and sulphamethoxazole / trimethoprim. Additionally, it is chemically incompatible with ceftriaxone sodium.

Shelf Life

Before opening: 24 months

After opening: From a microbiological point of view, unless the method of opening precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.

Special precautions for storage

Store in the original package (overwrap and carton) until ready to use in order to protect from light.

**MOCK-UP TYPE**

- | | |
|---|------------------------------------|
| <input type="checkbox"/> box | <input type="checkbox"/> overwrap |
| <input checked="" type="checkbox"/> leaflet | <input type="checkbox"/> blisters |
| <input type="checkbox"/> label | <input type="checkbox"/> box label |
| <input type="checkbox"/> bag | <input type="checkbox"/> other: |

PRODUCT*Linezolid*

Country

UK

Dimensions

235 x 680

ADC code

adc code

Visa

*RTo***PANTONES**

293u

Version: 01